Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

RPRX

Royalty Pharma plc

May 02 • 04:00PM ET

28.76

Dollar change +0.69
Percentage change 2.46	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VO VXF VTV VOE VYM VHT IWR IHE IWD

Index	-	P/E	11.34	EPS (ttm)	2.54	Insider Own	15.07%	Shs Outstand	446.69M	Perf Week	2.31%
Market Cap	12.97B	Forward P/E	6.59	EPS next Y	4.36	Insider Trans	-2.12%	Shs Float	383.02M	Perf Month	-0.14%
Income	1.13B	PEG	3.54	EPS next Q	0.99	Inst Own	67.94%	Short Float	3.70%	Perf Quarter	0.28%
Sales	2.35B	P/S	5.51	EPS this Y	-12.01%	Inst Trans	1.54%	Short Ratio	4.91	Perf Half Y	7.03%
Book/sh	14.61	P/B	1.97	EPS next Y	10.68%	ROA	6.84%	Short Interest	14.15M	Perf Year	-17.97%
Cash/sh	1.10	P/C	26.19	EPS next 5Y	3.20%	ROE	18.68%	52W Range	25.92 - 35.76	Perf YTD	2.39%
Dividend Est.	0.89 (3.10%)	P/FCF	4.28	EPS past 5Y	2.23%	ROI	8.96%	52W High	-19.57%	Beta	0.47
Dividend TTM	0.81 (2.82%)	Quick Ratio	7.90	Sales past 5Y	5.78%	Gross Margin	-	52W Low	10.96%	ATR (14)	0.60
Dividend Ex-Date	May 16, 2024	Current Ratio	7.90	EPS Y/Y TTM	2147.21%	Oper. Margin	63.38%	RSI (14)	52.25	Volatility	1.81% 2.18%
Employees	89	Debt/Eq	0.94	Sales Y/Y TTM	5.23%	Profit Margin	48.18%	Recom	1.20	Target Price	42.37
Option/Short	Yes / Yes	LT Debt/Eq	0.94	EPS Q/Q	207.50%	Payout	31.57%	Rel Volume	1.37	Prev Close	28.07
Sales Surprise	-0.48%	EPS Surprise	13.74%	Sales Q/Q	5.30%	Earnings	May 09 BMO	Avg Volume	2.88M	Price	28.76
SMA20	1.52%	SMA50	-2.44%	SMA200	0.04%	Trades		Volume	3,939,055	Change	2.46%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-14-22	Resumed	UBS	Buy	$47
May-13-22	Initiated	Scotiabank	Sector Outperform	$53
Apr-27-22	Initiated	Goldman	Buy	$56
Apr-14-22	Upgrade	JP Morgan	Neutral → Overweight	$50
Apr-06-22	Resumed	Morgan Stanley	Overweight	$48
Oct-29-21	Upgrade	Citigroup	Neutral → Buy	$50
Jul-30-21	Initiated	Tigress Financial	Buy	$50
Nov-09-20	Upgrade	UBS	Neutral → Buy	$52 → $51
Jul-14-20	Initiated	Evercore ISI	In-line
Jul-13-20	Initiated	UBS	Neutral	$52
Jul-13-20	Initiated	SunTrust	Buy	$56
Jul-13-20	Initiated	Morgan Stanley	Equal-Weight	$51
Jul-13-20	Initiated	JP Morgan	Neutral	$50
Jul-13-20	Initiated	Goldman	Neutral	$47
Jul-13-20	Initiated	Cowen	Outperform	$55
Jul-13-20	Initiated	Citigroup	Neutral	$50
Jul-13-20	Initiated	BofA Securities	Buy	$55

Show Previous Ratings

Today 04:01PM	Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma (Business Wire)
10:01AM	Royalty Pharma (RPRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-30-24 08:37AM	PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-19-24 08:15AM	Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 (GlobeNewswire)
Apr-17-24 08:15AM	Royalty Pharma Declares Second Quarter 2024 Dividend (GlobeNewswire)
08:50AM	Loading…
Mar-17-24 08:50AM	30 Biggest Biotechnology Companies in the World (Insider Monkey)
Feb-28-24 04:15PM	Royalty Pharma to Present at TD Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-20-24 12:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-17-24 12:15AM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Feb-16-24 03:30PM	Royalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
09:45AM	Royalty Pharma plc (NASDAQ:RPRX) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:04AM	Royalty Pharma PLC (RPRX): A Strategic SWOT Insight (GuruFocus.com)
Feb-15-24 11:08PM	Analyst Report: Royalty Pharma plc (Morningstar Research)
07:58AM	Royalty Pharma PLC (RPRX) Earnings Report: A Detailed Analysis (GuruFocus.com)
07:30AM	Royalty Pharma Reports Q4 and Full Year 2023 Results (GlobeNewswire)
01:04AM	Loading…
Jan-31-24 01:04AM	What Makes Royalty Pharma plc (RPRX) a Compelling Stock? (Insider Monkey)
Jan-30-24 04:15PM	Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024 (GlobeNewswire)
Jan-19-24 08:15AM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
Jan-08-24 07:00AM	Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-23 05:30AM	Should You Sell Royalty Pharma plc (RPRX)? (Insider Monkey)
Nov-27-23 04:15PM	Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference (GlobeNewswire)
Nov-13-23 08:10AM	Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program (GlobeNewswire)
08:00AM	Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program (Business Wire)
Nov-09-23 04:33PM	Royalty Pharma plc (NASDAQ:RPRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:15AM	The Royalty Pharma PLC (RPRX) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-08-23 07:00AM	Royalty Pharma Reports Third Quarter 2023 Results (GlobeNewswire)
Oct-19-23 07:59AM	Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi (GlobeNewswire)
Oct-16-23 04:15PM	Royalty Pharma Declares Fourth Quarter 2023 Dividend (GlobeNewswire)
Oct-11-23 04:15PM	Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023 (GlobeNewswire)
Sep-21-23 08:25AM	Royalty Pharma Appoints Eric Schneider as Chief Technology Officer (GlobeNewswire)
04:15PM	Loading…
Sep-05-23 04:15PM	Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement (GlobeNewswire)
04:01PM	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement (GlobeNewswire)
08:25AM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-24-23 06:30AM	Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg) (GlobeNewswire)
Aug-08-23 07:00AM	Royalty Pharma Reports Second Quarter 2023 Results (GlobeNewswire)
Jul-18-23 04:15PM	Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023 (GlobeNewswire)
Jul-17-23 04:15PM	Royalty Pharma Declares Third Quarter 2023 Dividend (GlobeNewswire)
Jun-18-23 08:58AM	Institutional owners may consider drastic measures as Royalty Pharma plc's (NASDAQ:RPRX) recent US$453m drop adds to long-term losses (Simply Wall St.)
Jun-07-23 08:15AM	Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
May-22-23 07:52PM	Goldman Sachs Likes These 2 Stocks, Insiders Just Poured Millions Into Them Heres Why You Might Want to Ride Their Coattails (TipRanks)
May-13-23 08:15AM	Here's Why We're Wary Of Buying Royalty Pharma's (NASDAQ:RPRX) For Its Upcoming Dividend (Simply Wall St.)
May-11-23 10:42AM	Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's (Simply Wall St.)
May-09-23 07:00AM	Royalty Pharma Reports First Quarter 2023 Results (GlobeNewswire)
May-03-23 04:15PM	Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference (GlobeNewswire)
Apr-20-23 06:15AM	Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20 (Simply Wall St.)
Apr-17-23 08:15AM	Royalty Pharma Declares Second Quarter 2023 Dividend (GlobeNewswire)
Apr-13-23 09:01AM	Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023 (GlobeNewswire)
Apr-05-23 06:17AM	Is Royalty Pharma plc's (NASDAQ:RPRX) Recent Price Movement Underpinned By Its Weak Fundamentals? (Simply Wall St.)
Mar-31-23 06:36AM	Daily Vickers Top Buyers & Sellers for 03/31/2023 (Argus Research)
Mar-27-23 07:30AM	Royalty Pharma Announces $1.0 Billion Share Repurchase Program (GlobeNewswire) +5.53%
Mar-23-23 07:00AM	Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million (GlobeNewswire)
03:00AM	PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million (Business Wire)
Mar-15-23 08:00AM	Royalty Pharma Raises Full Year 2023 Guidance (GlobeNewswire)
Mar-08-23 05:16AM	Optimism around Royalty Pharma (NASDAQ:RPRX) delivering new earnings growth may be shrinking as stock declines 3.5% this past week (Simply Wall St.)
Mar-01-23 08:15AM	Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments (GlobeNewswire)
Feb-15-23 07:00AM	Royalty Pharma Reports Q4 and Full Year 2022 Results (GlobeNewswire)
Feb-09-23 04:15PM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-03-23 09:19AM	Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20 (Simply Wall St.)
Jan-18-23 08:25AM	Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023 (GlobeNewswire)
Jan-12-23 05:01AM	Royalty Pharma's (NASDAQ:RPRX) Shareholders Will Receive A Bigger Dividend Than Last Year (Simply Wall St.)
Jan-09-23 09:25AM	Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:15AM	Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis Genetic Medicines and Commercial Readiness (GlobeNewswire)
09:05AM	Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness (PR Newswire)
08:30AM	Royalty Pharma Announces Dividend Increase (GlobeNewswire)
06:35AM	In the wake of Royalty Pharma plc's (NASDAQ:RPRX) latest US$631m market cap drop, institutional owners may be forced to take severe actions (Simply Wall St.)
Jan-04-23 04:15PM	Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9 (GlobeNewswire)
Dec-15-22 08:15AM	Royalty Pharma Announces Expansion of Senior Leadership Team (GlobeNewswire)
Dec-08-22 05:23AM	Is Royalty Pharma plc (NASDAQ:RPRX) Trading At A 50% Discount? (Simply Wall St.)
Nov-28-22 04:26PM	Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference (GlobeNewswire)
Nov-09-22 08:49AM	Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones (GlobeNewswire)
08:10AM	Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones (Business Wire)
Nov-08-22 07:00AM	Royalty Pharma Reports Third Quarter 2022 Results (GlobeNewswire)
Oct-18-22 08:30AM	Royalty Pharma to Announce Third Quarter 2022 Financial Results on November 8, 2022 (GlobeNewswire)
Oct-17-22 08:30AM	Royalty Pharma Declares Fourth Quarter 2022 Dividend (GlobeNewswire)
Oct-12-22 04:15PM	Royalty Pharma Announces Expansion of Leadership Team (GlobeNewswire)
07:00AM	Royalty Pharma Announces R&D Funding Collaboration With Merck (GlobeNewswire)
Sep-09-22 09:15AM	Royalty Pharma's (NASDAQ:RPRX) investors will be pleased with their 14% return over the last year (Simply Wall St.)
Sep-06-22 04:15PM	Royalty Pharma to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-13-22 08:05AM	Here's Why We're Wary Of Buying Royalty Pharma's (NASDAQ:RPRX) For Its Upcoming Dividend (Simply Wall St.)
Aug-04-22 07:00AM	Royalty Pharma Reports Second Quarter 2022 Results (GlobeNewswire)
Jul-15-22 08:15AM	Royalty Pharma Declares Third Quarter 2022 Dividend (GlobeNewswire)
Jul-14-22 06:04PM	Why 2 drug royalty deals worth close to $2 billion could signal the future (American City Business Journals)
08:58AM	Theravance sets up deal to sell rights to asthma drug to Royalty Pharma (MarketWatch)
08:30AM	Royalty Pharma to Announce Second Quarter 2022 Financial Results on August 4, 2022 (GlobeNewswire)
Jul-13-22 04:25PM	Royalty Pharma Agrees to Acquire Royalty Interest in TRELEGY ELLIPTA From Theravance and Innoviva for $1.31 Billion and Potential Milestones of $300 Million (GlobeNewswire)
04:05PM	Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value (PR Newswire)
Jul-04-22 02:44PM	What Kind Of Shareholders Hold The Majority In Royalty Pharma plc's (NASDAQ:RPRX) Shares? (Simply Wall St.)
Jun-30-22 06:06PM	Blueprint Medicines signs deals for up to $1.25B in cash, earnouts (American City Business Journals)
08:42AM	Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billion (MarketWatch)
07:31AM	Royalty Pharma Acquires Royalty Interest in Gavreto From Blueprint Medicines for up to $340 Million (GlobeNewswire)
07:15AM	Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma (PR Newswire)
Jun-27-22 02:12AM	Ipsen to acquire U.S.-based Epizyme for $247 million. (MarketWatch)
Jun-08-22 08:30AM	Royalty Pharma to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference (GlobeNewswire)
Jun-04-22 08:22AM	Royalty Pharma plc's (NASDAQ:RPRX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? (Simply Wall St.)
May-23-22 08:30AM	Royalty Pharma to Present at the UBS Global Healthcare Conference 2022 (GlobeNewswire)
May-17-22 07:00AM	Royalty Pharma Investor Day Highlights Stronger Growth Outlook and the Power of Its Unique Business Model to Drive Value for All Stakeholders (GlobeNewswire)
May-05-22 07:00AM	Royalty Pharma Reports First Quarter 2022 Results (GlobeNewswire) -5.63%
May-04-22 03:32PM	With Royalty Pharma plc (NASDAQ:RPRX) It Looks Like You'll Get What You Pay For (Simply Wall St.)
Apr-18-22 08:00AM	Royalty Pharma Declares Second Quarter 2022 Dividend (GlobeNewswire)
Apr-13-22 08:00AM	Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022 (GlobeNewswire)

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIGGS RORY B	Director	Jan 04 '24	Sale	27.55	35,702	983,504	20,099	Jan 04 05:16 PM
RIGGS RORY B	Director	Jan 03 '24	Sale	27.79	199,098	5,532,276	55,801	Jan 04 05:16 PM
RIGGS RORY B	Director	Jan 02 '24	Sale	28.52	235,200	6,707,081	254,899	Jan 04 05:16 PM
Avara Management Ltd	10% Owner	Dec 29 '23	Sale	28.04	65,803	1,845,406	2,477,520	Jan 03 04:31 PM
Avara Management Ltd	10% Owner	Dec 28 '23	Sale	28.20	209,863	5,918,934	2,543,323	Dec 29 04:29 PM
Avara Management Ltd	10% Owner	Dec 27 '23	Sale	28.01	41,729	1,168,754	2,753,186	Dec 29 04:29 PM
Avara Management Ltd	10% Owner	Dec 15 '23	Sale	28.01	10,229	286,499	2,794,915	Dec 19 04:30 PM
Avara Management Ltd	10% Owner	Dec 14 '23	Sale	28.91	364,441	10,534,276	2,805,144	Dec 15 04:31 PM
Avara Management Ltd	10% Owner	Dec 13 '23	Sale	28.95	307,935	8,916,012	3,169,585	Dec 15 04:31 PM
Coyne Terrance P.	EVP & CFO	Aug 10 '23	Sale	30.75	37,500	1,153,091	790,000	Aug 11 05:00 PM
Coyne Terrance P.	EVP & CFO	Aug 09 '23	Sale	30.72	37,500	1,151,936	827,500	Aug 11 05:00 PM
Coyne Terrance P.	EVP & CFO	Jul 13 '23	Sale	30.93	37,500	1,159,958	865,000	Jul 14 06:09 PM
Coyne Terrance P.	EVP & CFO	Jul 12 '23	Sale	31.07	37,500	1,165,256	902,500	Jul 14 06:09 PM
Legorreta Pablo G.	CEO, Chairman of the Board	Jun 28 '23	Buy	29.51	130,000	3,836,768	600,000	Jun 28 04:01 PM
Legorreta Pablo G.	CEO, Chairman of the Board	Jun 13 '23	Buy	32.78	45,000	1,474,902	470,000	Jun 13 04:01 PM
Legorreta Pablo G.	CEO, Chairman of the Board	Jun 12 '23	Buy	33.00	45,000	1,484,946	425,000	Jun 13 04:01 PM
Lloyd George W.	EVP, Investments & CLO	Jun 06 '23	Sale	33.82	79,099	2,674,796	30,000	Jun 06 05:07 PM
Lloyd George W.	EVP, Investments & CLO	Jun 05 '23	Sale	33.54	19,215	644,446	109,099	Jun 06 05:07 PM
Lloyd George W.	EVP, Investments & CLO	Jun 02 '23	Sale	33.64	93,907	3,159,345	120,000	Jun 06 05:07 PM
Legorreta Pablo G.	CEO, Chairman of the Board	May 24 '23	Buy	32.25	150,000	4,837,440	380,000	May 24 06:45 PM
RIGGS RORY B	Director	May 22 '23	Sale	32.82	1,750,000	57,435,000	6,762	May 22 08:36 PM
Legorreta Pablo G.	CEO, Chairman of the Board	May 17 '23	Buy	32.94	69,612	2,293,096	230,000	May 17 06:41 PM
Legorreta Pablo G.	CEO, Chairman of the Board	May 16 '23	Buy	33.57	160,388	5,383,728	160,388	May 17 06:41 PM

Open in Screener

CBUS

Cibus Inc

May 02 • 04:00PM ET

16.74

Dollar change -0.37
Percentage change -2.16	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-28.14	Insider Own	33.48%	Shs Outstand	21.24M	Perf Week	7.72%
Market Cap	351.37M	Forward P/E	-	EPS next Y	-2.25	Insider Trans	7.94%	Shs Float	13.96M	Perf Month	-15.62%
Income	-267.63M	PEG	-	EPS next Q	-1.01	Inst Own	26.95%	Short Float	2.71%	Perf Quarter	-2.96%
Sales	1.82M	P/S	193.06	EPS this Y	88.32%	Inst Trans	-17.16%	Short Ratio	5.71	Perf Half Y	55.72%
Book/sh	13.82	P/B	1.21	EPS next Y	25.58%	ROA	-94.43%	Short Interest	0.38M	Perf Year	5.95%
Cash/sh	1.56	P/C	10.75	EPS next 5Y	-	ROE	-178.00%	52W Range	8.90 - 38.85	Perf YTD	-14.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.61%	ROI	-86.01%	52W High	-56.91%	Beta	1.97
Dividend TTM	-	Quick Ratio	1.37	Sales past 5Y	837.06%	Gross Margin	-332.80%	52W Low	88.09%	ATR (14)	1.17
Dividend Ex-Date	-	Current Ratio	1.65	EPS Y/Y TTM	-51.01%	Oper. Margin	-3823.01%	RSI (14)	45.51	Volatility	4.81% 6.51%
Employees	-	Debt/Eq	0.08	Sales Y/Y TTM	1057.32%	Profit Margin	-14729.06%	Recom	1.67	Target Price	23.00
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	-329.99%	Payout	-	Rel Volume	1.01	Prev Close	17.11
Sales Surprise	186.87%	EPS Surprise	-780.42%	Sales Q/Q	2526.19%	Earnings	May 09 AMC	Avg Volume	66.22K	Price	16.74
SMA20	-2.66%	SMA50	-9.30%	SMA200	-1.81%	Trades		Volume	66,947	Change	-2.16%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-09-23	Initiated	H.C. Wainwright	Buy	$25
Jul-19-23	Resumed	Canaccord Genuity	Buy	$30

Apr-25-24 07:00AM	Cibus to Report First Quarter 2024 Financial Results on May 9, 2024 and Host Conference Call (GlobeNewswire)
Mar-25-24 03:16PM	Cibus (CBUS) Reports Q4 Loss, Tops Revenue Estimates (Revised) (Zacks) +5.25%
Mar-22-24 01:03PM	Cibus, Inc. (NASDAQ:CBUS) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.10%
Mar-21-24 08:52PM	CBUS Stock Earnings: Cibus Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -9.01%
04:05PM	Cibus Reports Fourth Quarter Financial Results and Provides Business Update (GlobeNewswire)
08:30AM	Loading…
Mar-19-24 08:30AM	Cibus Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024 (GlobeNewswire) -6.80%
Mar-18-24 08:26AM	Cibus (CBUS) Moves 6.7% Higher: Will This Strength Last? (Zacks) +5.13%
Mar-13-24 07:35AM	Cibus to Participate in the 36th Annual Roth Conference (GlobeNewswire)
Mar-07-24 07:00AM	Cibus to Report Fourth Quarter 2023 Financial Results on March 21, 2024 and Host Conference Call (GlobeNewswire)
Feb-26-24 07:00AM	Cibus and Loveland Products Collaborate to Develop and Sell Rice Traits in the US (GlobeNewswire)
Feb-07-24 12:51PM	European Parliament Votes to Support Proposal for the Regulation of New Genomic Techniques (GlobeNewswire)
Jan-25-24 04:30PM	European Parliaments Environment Committee Votes to Support New Proposal for the Regulation of New Genomic Techniques (GlobeNewswire)
Jan-17-24 07:00AM	Cibus 2023 Field Trial Results Move Developed Traits Closer to Product Sales (GlobeNewswire)
Jan-09-24 07:00AM	Cibus Announces Major Breakthrough in Wheat Regeneration from Single Cells (GlobeNewswire) +6.27%
Jan-04-24 07:30AM	Cibus Enters into a Latin America Collaboration Agreement with Interoc to deliver rice growers an innovative rice weed control system (GlobeNewswire)
07:30AM	Loading…
Dec-12-23 07:30AM	Cibus Announces $20.3 Million Registered Direct Offering (GlobeNewswire)
Dec-01-23 08:00AM	European Union Notifies Trading Partners on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques (GlobeNewswire) +10.34%
Nov-30-23 08:00AM	Cibus Announces New Publication: Industrial Scale Gene Editing in Brassica napus (GlobeNewswire)
Nov-09-23 04:05PM	Cibus Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:00AM	European Parliament Releases Draft Report on the Proposal for the Regulation of Plants Obtained from New Genomic Techniques (GlobeNewswire)
Nov-02-23 04:05PM	Cibus to Report Third Quarter 2023 Financial Results on November 9, 2023 and Host Conference Call (GlobeNewswire)
Oct-09-23 09:33AM	Oracle upgraded, Spotify downgraded: Wall Street's top analyst calls (The Fly) -8.67%
Sep-18-23 05:23PM	Jim Collins to Join Cibus Board of Directors (GlobeNewswire) +15.85%
Sep-05-23 08:00AM	Cibus to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire) +11.27%
Aug-09-23 05:00PM	Cibus Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-23 12:30PM	Steve Berreth Appointed as General Counsel and Corporate Secretary (GlobeNewswire) +5.33%
07:00AM	Cibus to Report Second Quarter 2023 Financial Results on August 10, 2023 and Host Conference Call (GlobeNewswire)
Aug-02-23 04:05PM	Cibus to Present at the Canaccord 43rd Annual Growth Conference (GlobeNewswire)
Jul-12-23 08:30AM	Cibus Opens Dedicated, High-throughput Gene Editing Facility for Trait Production (GlobeNewswire)
Jul-05-23 04:05PM	Cibus Welcomes European Commission Proposal on Regulation of Plants Obtained from New Genomic Techniques (GlobeNewswire) +26.93%
08:45AM	Loading…
Jun-15-23 08:45AM	Cibus Applauds the Genetic Technology (Precision Breeding) Act 2023 Passed in the United Kingdom (GlobeNewswire) +10.78%
07:00AM	Cibus to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-07-23 07:00AM	Cibus White Mold Resistance Trait in Canola Achieves Another Important Milestone (GlobeNewswire)
Jun-01-23 07:00AM	Cibus Announces Closing of Merger with Calyxt to Create Industry Leading Precision Gene Editing and Trait Development Company (GlobeNewswire) -17.30%

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as Canola, Rice, Soybean, Corn and Wheat. The company was founded in 2010 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RIGGS RORY B	Chief Executive Officer	Dec 12 '23	Buy	10.58	517,107	5,470,992	1,622,495	Dec 14 05:10 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

RPRX

Royalty Pharma plc

CBUS

Cibus Inc

Upgrade your FINVIZ experience